Overview of the population of patients with advanced Parkinson’s disease (aPD) initiating therapy with levodopa-carbidopa intestinal gel (LCIG): POMPE-PARK study on French health insurance data (2013-2017)
Objective: To quantify the number of French aPD patients initiating continuous delivery of LCIG from 2013 to 2017 and to describe their demographic, clinical and…LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset
Objective: To investigate the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation on the anti-parkinsonian action of a low dose of…Comparison of gastrointestinal transit times in typical and erratic levodopa-responders in patients with Parkinson’s disease.
Objective: To determine if altered transit time in the various segments of the gastrointestinal (GI) tract relates to the variability of clinical responses and serum…Tinospora Cordifolia protects against Rotenone induced degeneration of dopaminergic neurons in mouse model of Parkinson’s disease
Objective: To explore the neuroprotective mechanisms of T. cordifolia ethanolic extract against Rotenone (ROT)-intoxicated mouse model through proteomics approach. Background: The death of dopaminergic (DAergic)…Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson’s Disease
Objective: Our study aims to analyze the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) in Parkinson's disease (PD). Background: Oral Levodopa is considered to…Effects of levodopa dose on temporal dynamics of cortical activity and postural control in people with Parkinson’s disease
Objective: The purpose of this study was to evaluate the temporal dynamics of cortical activity and postural control for the first levodopa dose of the…Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.
Objective: To evaluate whether Helicobactor pylori (H.pylori) infection affects the pharmacokinetics of L-DOPA in patients with Parkinson’s disease (PD). Background: H. pylori infects gastric mucosa…Quantitative 3D movement analysis detects motor improvement earlier than MDS-UPDRS in a levodopa challenge test
Objective: Characterize the response of gait in a levodopa challenge test (LCT) in PD using inertial sensor-based 3D movement analysis and MDS-UPDRS. Background: Quantitative 3D…CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)
Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 62
- Next Page »